Mateja Lobnik

Medis

Medis is the leading commercialization company in the region of Central and Eastern Europe (CEE) focused on innovative medicinal products. For the past 34 years, we and our global pharma and biotech partners have been creating success stories with the single aim of providing access to innovative therapies for patients in CEE. We operate in a region that consists of small and complex markets with diverse healthcare systems. Despite this challenging environment, we recognize the high potential of the region and strive to ensure health equity for this underserved part of Europe. Our business areas • Therapeutics • Hospital Care • Consumer Health • Aesthetics Our value to partners • Direct local presence in 18 CEE countries • Full commercialization of medicinal products • Single point of contact and delivery • Strategic & localized market access approach • Highest compliance standards • Financial and credit excellence Medis is a member of the World Orphan Drug Alliance (WODA) – global alliance of full-service regional distributors for orphan products. WODA covers 76 countries in Central and Eastern Europe, Greater China, Israel, Greece, Malta, Cyprus, Latin America, Middle East, North Africa & Turkey, Switzerland. Out-licensing Become our commercialization partner and benefit from advanced, ready-to-launch consumer health products which are already marketed in 20 countries and expanding to more. More information: www.medis.com/en/international-business/ Major Partners • Therapeutics: Bial – Biogen – Besins – HRA Pharma – Mundipharma – Pierre Fabre – Santen – UCB • Hospital Care: Abbott – Aesculap – Asahi Medical – Biotest – B. Braun – Cytosorbents – Paion • Consumer Health: Pleuran – Ricerpharma – Karo Healthcare – Merz – Pohl Boskamp – UP – URGO • Aesthetics: Merz Aesthetics • Out-licensing partners: Ferrer – Pharmalink – Stada Get in touch with us business.development@medis.com